Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Windmill Hill Asset Management Ltd

Windmill Hill Asset Management Ltd raised its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 299.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 104,373 shares of the company’s stock after purchasing an additional 78,252 shares during the quarter. Neumora Therapeutics comprises 1.1% of Windmill Hill Asset Management Ltd’s investment portfolio, making the stock its 12th biggest position. Windmill Hill Asset Management Ltd owned 0.06% of Neumora Therapeutics worth $1,106,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC lifted its position in Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after buying an additional 694,385 shares during the last quarter. State Street Corp lifted its holdings in shares of Neumora Therapeutics by 65.3% in the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after acquiring an additional 707,409 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after purchasing an additional 406,891 shares during the period. Auour Investments LLC acquired a new stake in Neumora Therapeutics in the 3rd quarter valued at approximately $3,302,000. Finally, Cerity Partners LLC purchased a new stake in Neumora Therapeutics in the third quarter valued at approximately $3,209,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NMRA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research note on Thursday, January 2nd. Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $29.00 to $4.00 in a research report on Thursday, January 2nd. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a report on Friday, January 3rd. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Neumora Therapeutics Stock Performance

Shares of NMRA opened at $1.95 on Friday. The firm’s fifty day simple moving average is $6.30 and its 200-day simple moving average is $10.20. Neumora Therapeutics, Inc. has a twelve month low of $1.81 and a twelve month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the firm earned ($1.14) earnings per share. Sell-side analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.